STN

FILE 'PS' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:29:53 ON 19 DEC 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'TOXCENTER' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 13:29:53 ON 19 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:29:53 ON 19 DEC 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 13:29:53 ON 19 DEC 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s method and produce and peptides
  21 FILES SEARCHED...
  46 FILES SEARCHED...
L1   129634 METHOD AND PRODUCE AND PEPTIDES

=> dup rem
ENTER L# LIST OR (END):L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
129634 ANSWERS REQUESTED EXCEEDS MAXIMUM ALLOWED OF 50000
You may process up to 50,000 answers per command. Please try to
narrow your search until your resulting L# answer set is within the
maximum number of answers.

=> s atrial natriuretic peptide
  21 FILES SEARCHED...
  62 FILES SEARCHED...
L2   70156 ATRIAL NATRIURETIC PEPTIDE

=> s L1 and L2
  40 FILES SEARCHED...
L3   1046 L1 AND L2

=> s L3 and E.coli

```
  21 FILES SEARCHED...
  49 FILES SEARCHED...
L4          425 L3 AND E.COLI

=> d his

     (FILE 'HOME' ENTERED AT 13:29:35 ON 19 DEC 2006)

     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB,
     CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2,
     DRUGU, EMBAL, EMBASE, ESBIOBASE, FOMAD, ...' ENTERED AT 13:29:53 ON 19
     DEC 2006
L1        129634 S METHOD AND PRODUCE AND PEPTIDES
L2         70156 S ATRIAL NATRIURETIC PEPTIDE
L3          1046 S L1 AND L2
L4           425 S L3 AND E.COLI

=> s L4 and recombinant
  46 FILES SEARCHED...
L5          389 L4 AND RECOMBINANT

=> dup rem
ENTER L# LIST OR (END):L5
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L5
L6           348 DUP REM L5 (41 DUPLICATES REMOVED)

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:N

=> d his

     (FILE 'HOME' ENTERED AT 13:29:35 ON 19 DEC 2006)

     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB,
     CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2,
     DRUGU, EMBAL, EMBASE, ESBIOBASE, FOMAD, ...' ENTERED AT 13:29:53 ON 19
     DEC 2006
L1        129634 S METHOD AND PRODUCE AND PEPTIDES
L2         70156 S ATRIAL NATRIURETIC PEPTIDE
L3          1046 S L1 AND L2
L4           425 S L3 AND E.COLI
L5           389 S L4 AND RECOMBINANT
L6           348 DUP REM L5 (41 DUPLICATES REMOVED)

=> s L6 and ANP
  30 FILES SEARCHED...
  59 FILES SEARCHED...
L7          179 L6 AND ANP

=> dup rem
ENTER L# LIST OR (END):L7
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L7
```

```
L8          179 DUP REM L7 (0 DUPLICATES REMOVED)

=> s L8 and o-acetyserine
  24 FILES SEARCHED...
  54 FILES SEARCHED...
L9            0 L8 AND O-ACETYSERINE

=> s L8 and o-acetylserine
  18 FILES SEARCHED...
  30 FILES SEARCHED...
  53 FILES SEARCHED...
L10           0 L8 AND O-ACETYLSERINE

=> d his

     (FILE 'HOME' ENTERED AT 13:29:35 ON 19 DEC 2006)

     FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB,
     CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2,
     DRUGU, EMBAL, EMBASE, ESBIOBASE, FOMAD, ...' ENTERED AT 13:29:53 ON 19
     DEC 2006
L1        129634 S METHOD AND PRODUCE AND PEPTIDES
L2         70156 S ATRIAL NATRIURETIC PEPTIDE
L3          1046 S L1 AND L2
L4           425 S L3 AND E.COLI
L5           389 S L4 AND RECOMBINANT
L6           348 DUP REM L5 (41 DUPLICATES REMOVED)
L7           179 S L6 AND ANP
L8           179 DUP REM L7 (0 DUPLICATES REMOVED)
L9             0 S L8 AND O-ACETYSERINE
L10            0 S L8 AND O-ACETYLSERINE

=> d L8 1-179 ibib,abs

L8   ANSWER 1 OF 179  USPATFULL on STN
ACCESSION NUMBER:        2006:321760 USPATFULL
TITLE:                   Methods for detection of biological
                         substances
INVENTOR(S):             Henkin, Robert I., Bethesda, MD, UNITED STATES

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2006275801      A1   20061207
APPLICATION INFO.:       US 2006-415942     A1   20060501  (11)

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2006-743495P    20060315 (60)
                         US 2005-676252P    20050429 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD,
                         PALO ALTO, CA, 94304-1050, US
NUMBER OF CLAIMS:        41
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      12 Drawing Page(s)
LINE COUNT:              4840
AB       The invention is directed to a method of detecting a
         biological substance in the nasal secretion and diagnosing a disease
         following the detection of the biological substance wherein the
         biological substance is not related to a respiratory disease. The
         invention also provides treatment of the diseases following the
         detection of the biological substance and/or diagnosis of the disease.
```

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6372957	B1	20020416
APPLICATION INFO.:	US 1999-438075		19991110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-107755P	19981110 (60)
	US 1998-108083P	19981112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Crouch, Deborah
ASSISTANT EXAMINER: Woitach, Joseph T.
LEGAL REPRESENTATIVE: Fulbright & Jaworski, LLP
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 3257
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to cardiac hypertrophy. More particularly, the present invention defines the molecular events linking calcium stimulation to cardiac hypertrophy. More specifically, the present invention shows that Ca++ stimulation of the hypertroplic response is mediated through MEF2. Thus, the present invention provides methods of treating cardiac hypertrophy as well as transgenic constructs for preparing transgenic animals. Further provided are methods of using the transgenic animals of the present invention, or cells isolated therefrom, for the detection of compounds having therapeutic activity toward cardiac hypertrophy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 137 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2001:212417 USPATFULL
TITLE: In situ bioreactors and methods of use thereof
INVENTOR(S): Pierce, Glenn, Rancho Santa Fe, CA, United States
Chandler, Lois Ann, Encinitas, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001044413	A1	20011122
APPLICATION INFO.:	US 2000-729644	A1	20001130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-168470P	19991201 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 104
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 2302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides in situ bioreactors comprising a biocompatible substance comprising nucleic acid molecules and capable of cellular ingrowth and systemic delivery of a bioactive agent. Also provided are compositions, devices, and kits comprising the same. In various embodiments the biocompatible substance comprises a matrix and at least one nucleic acid molecule encoding a bioactive agent. In other embodiments bioreactors are provided wherein a first gene that encodes a

growth factor is present and a second gene encoding a bioactive agent is present during manufacture or provided to the bioreactor following manufacture or implantation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 138 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2001:190719 USPATFULL
TITLE: Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
INVENTOR(S): Ekwuribe, Nnochiri, Cary, NC, United States
Ramaswamy, Muthukumar, Cary, NC, United States
Rajagopalan, Jayanthi Sethuraman, Cary, NC, United States
PATENT ASSIGNEE(S): Nobex Corporation, Research Triangle Park, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6309633	B1	20011030	
APPLICATION INFO.:	US 1999-336548		19990619	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Myers Bigel Sibley & Sajovec, P.A.
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 49
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a drug-oligomer conjugate having the following general formula: ##STR1##

wherein D is a therapeutic drug moiety; H and H' are each a hydrophilic moiety, independently selected from the group consisting of straight or branched PEG polymers having from 2 to 130 PEG subunits, and sugars; L is a lipophilic moiety selected from the group consisting of alkyl groups having 2-26 carbon atoms, cholesterol, adamantane and fatty acids; o is a number from 1 to the maximum number of covalent bonding sites on H; m+n+p together have a value of at least one and not exceeding the total number of covalent bonding sites on D for the --H', --L and --H--L substituents; the H--L bond(s) are hydrolyzable and the D--L' bond(s), when present, are hydrolyzable; the conjugate being further characterized by one of the following: (i) m is 0 and p is at least 1; (ii) n is 0 and p is at least 1; (iii) m and n are each 0 and p is at least 1; (iv) p is 0 and m and n are each at least 1. The therapeutic drug moiety is preferably a therapeutic protein or peptide, preferably insulin or a functional equivalent thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 139 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2001:67794 USPATFULL
TITLE: Human respiratory syncytial virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6228983 B1 20010508
APPLICATION INFO.: US 1995-485264 19950607 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 Continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 Continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 62
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 32166
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a human respiratory syncytial virus protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107x178x4; or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 140 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2001:67655 USPATFULL
TITLE: Stimulating vascular growth by administration of DNA sequences encoding VEGF
INVENTOR(S): Wolff, Jon A., Madison, WI, United States
Duke, David J., Salem, OR, United States
Felgner, Philip L., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228844	B1	20010508
APPLICATION INFO.:	US 1997-979686		19971126 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-480039, filed on 7 Jun 1995, now patented, Pat. No. US 5693622 Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned Continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox, P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a method for delivering a pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is

taken up into the interior of the cell and has a pharmacological effect on the vertebrate such as inducing vascular growth. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 141 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:164489 USPATFULL
TITLE: Use of leukemia inhibitory factor and endothelin antagonists
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
King, Kathleen, Pacifica, CA, United States
Luis, Elizabeth, San Francisco, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Paoni, Nicholas F., Belmont, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6156733		20001205	
APPLICATION INFO.:	US 1998-23967		19980213	(9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-693826, filed on 26 Jul 1996, now patented, Pat. No. US 5837241 which is a continuation of Ser. No. US 1995-428002, filed on 24 Apr 1995, now patented, Pat. No. US 5573762, issued on 12 Nov 1996			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Johnson, Nancy A.			
LEGAL REPRESENTATIVE:	Hasak, Janet E., Conley, Deirdre L.			
NUMBER OF CLAIMS:	9			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 8 Drawing Page(s)			
LINE COUNT:	1638			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 142 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:142131 USPATFULL
TITLE: Process for the production of peptides by way of streptavidin fusion proteins
INVENTOR(S): Kopetzki, Erhard, Penzberg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Roche Diagnostics GmbH, Mannheim, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6136564		20001024	
	WO 9718314		19970522	
APPLICATION INFO.:	US 1998-68738		19980625	(9)
	WO 1996-EP4850		19961106	
			19980625	PCT 371 date
			19980625	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1995-19542702	19951116

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carson, Karen Cochrane
ASSISTANT EXAMINER: Srivastava, Devesh
LEGAL REPRESENTATIVE: Arent Fox Kintner Plotkin Kahn
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for recombinant preparation of peptides by expression of a DNA in micro-organisms, which DNA codes for a fusion protein made of streptavidin and one of the said peptides. Streptavidin and the peptide are bound by a peptide sequence which can be cleaved by an endoproteinase. The process also includes isolation of the insoluble, inactive protein, solubilisation of the inactive protein using a denaturant, dilution of the denaturant at a pH value of between 8.5 and 11 until cleaving of the fusion protein by an endoproteinase can take place, cleaving of the fusion protein, lowering of the pH value until streptavin and non-cleaved fusion protein precipitate, and cleaning of the desired peptide from the supernatant. Said process is particularly suitably for producing parathromone and urodilatin and fragments thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 143 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:121293 USPATFULL
TITLE: Assay for cardiac hypertrophy
INVENTOR(S): King, Kathleen, Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117650		20000912
APPLICATION INFO.:	US 1997-898911		19970723 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-452555, filed on 25 May 1995, now abandoned which is a continuation of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893 which is a continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gitomer, Ralph
LEGAL REPRESENTATIVE: Conley, Deirdre L.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4259
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An assay to test for hypertrophic activity in myocytes is described where wells are precoated with D-MEM/F-12 and fetal calf serum, plated with myocytes, cultured, and any change in size of the cells is determined. The growth medium may contain insulin, transferrin and aprotinin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 144 OF 179 USPATFULL on STN

ACCESSION NUMBER: 2000:105700 USPATFULL
TITLE: Production of polypeptides by use of novel protease deficient yeast strains
INVENTOR(S): Treichler, Hansjorg, Kanerkinden, Switzerland
Takabayashi, Kenji, Basel, Switzerland
Wolf, Dieter Heinrich, Gundelfingen, Germany, Federal Republic of
Heim, Jutta, Ramlinsburg, Switzerland
PATENT ASSIGNEE(S): Novartis Corporation, New York, NY, United States (U.S. corporation)
UCP Gen-Pharma AG, Kirchberg, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6103515		20000815
APPLICATION INFO.:	US 1992-895581		19920608 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-346670, filed on 3 May 1989, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1988-10524	19880504
	GB 1988-12627	19880527
	GB 1989-7110	19890329

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Low, Christopher S. F.
LEGAL REPRESENTATIVE: Lee, Michael U., McCormack, Myra H.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1920
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 145 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:98211 USPATFULL
TITLE: Human nucleic acid methylases
INVENTOR(S): Hillman, Jennifer L., Mountain View, CA, United States
Lal, Preeti, Santa Clara, CA, United States
Corley, Neil C., Mountain View, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
Yue, Henry, Sunnyvale, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6096526		20000801
APPLICATION INFO.:	US 1998-82310		19980520 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Srivastava, Devesh
LEGAL REPRESENTATIVE: Incyte Pharmaceuticals, Inc.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 10 Drawing Page(s)

LINE COUNT: 2590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a human nucleic acid methylases (HNAM) and polynucleotides which identify and encode HNAM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of HNAM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 146 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:95093 USPATFULL
TITLE: Isolated peptides derived from the Epstein-Barr virus containing fusion inhibitory domains
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6093794		20000725
APPLICATION INFO.:	US 1995-471913		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 147 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:67564 USPATFULL
TITLE: Methods for inhibition of membrane fusion-associated events, including influenza virus
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6068973 20000530
APPLICATION INFO.: US 1995-485551 19950607 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Park, Hankyel
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 12021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 148 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:57361 USPATFULL
TITLE: Compositions for inhibition of membrane fusion-associated events, including influenza virus transmission
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)
Duke University, Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6060065		20000509
APPLICATION INFO.:	US 1995-475668		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Parley, Hankyel T.
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 84 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19987
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to viral peptides referred to as "DP107- and DP178-like" peptides. Specifically, the invention

relates to isolated influenza A DP107- and DP178-like peptides which are identified by sequence search motif algorithms. The peptides of the invention exhibit antiviral activity believed to result from inhibition of viral induced fusogenic events.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 149 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:50515 USPATFULL
TITLE: Screening assays for compounds that inhibit membrane fusion-associated events
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Jr., Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6054265		20000425
APPLICATION INFO.:	US 1997-919597		19970926 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Stucker, Jeffrey
LEGAL REPRESENTATIVE: Pennie & Edmonds, LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 83 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 21307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 150 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:31219 USPATFULL
TITLE: Process for production of protein
INVENTOR(S): Yabuta, Masayuki, Tatebayashi, Japan
Ohsuye, Kazuhiro, Ohta, Japan
PATENT ASSIGNEE(S): Suntory Limited, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6037145		20000314
APPLICATION INFO.:	US 1995-523373		19950905 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-238595	19940907
	JP 1994-296028	19941107

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Kemmerer, Elizabeth C.
ASSISTANT EXAMINER: Lathrop, Brian
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the production of a desired polypeptide comprising the steps of: (1) transforming host cells with an expression vector comprising a gene coding for a fusion protein comprising a desired polypeptide and a protective polypeptide; (2) culturing the transformed host cells so as to express said gene to produce a fusion protein; and (3) excising the desired polypeptide from the fusion protein with a protease intrinsic to the host cells. According to the present invention, a large amount of a desired polypeptide can be produced at a low cost. Especially according to the present invention, a large amount of S. aureus V8 protease can be efficiently produced at low cost using a safe host such as E. coli according to gene recombination procedures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 151 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:12922 USPATFULL
TITLE: Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6020459		20000201
APPLICATION INFO.:	US 1995-484223		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 which is a continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 75
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 20335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 152 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:9527 USPATFULL
TITLE: Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
Langlois, Alphonse J., Durham, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6017536		20000125
APPLICATION INFO.:	US 1994-360107		19941220 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-255208, filed on 7 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 50 Drawing Figure(s); 62 Drawing Page(s)
LINE COUNT: 20227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through computer algorithms capable of recognizing the ALLMOTI5, 107+178+4, or PLZIP amino acid motifs. These motifs are associated with the antifusogenic and antiviral activities of the claimed peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 153 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:4792 USPATFULL
TITLE: Atrial natriuretic factor mutants and ischemic stroke
INVENTOR(S): Shimkets, Richard August, West Haven, CT, United States
PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013630		20000111
APPLICATION INFO.:	US 1997-916043		19970821 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Allen, Marianne P.
LEGAL REPRESENTATIVE: Elrifi, Ivor R.Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C., Johnson, David E.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 2390
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based upon the observation that a mutant atrial

natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 154 OF 179 USPATFULL on STN
ACCESSION NUMBER: 2000:4427 USPATFULL
TITLE: Measles virus peptides with antifusogenic and antiviral activities
INVENTOR(S): Barney, Shawn O'Lin, Cary, NC, United States
Lambert, Dennis Michael, Cary, NC, United States
Petteway, Stephen Robert, Cary, NC, United States
PATENT ASSIGNEE(S): Trimeris, Inc., Durham, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6013263		20000111
APPLICATION INFO.:	US 1995-486099		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-470896, filed on 6 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-360107, filed on 20 Dec 1994 Ser. No. Ser. No. US 1994-255208, filed on 7 Jun 1994 And Ser. No. US 1993-73028, filed on 7 Jun 1993, now patented, Pat. No. US 5464933
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Laurie
ASSISTANT EXAMINER: Parkin, Jeffrey S.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 52 Drawing Figure(s); 83 Drawing Page(s)
LINE COUNT: 19827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 155 OF 179 USPATFULL on STN
ACCESSION NUMBER: 1999:106437 USPATFULL
TITLE: Recombinant canine brain natriuretic peptide
INVENTOR(S): Seilhamer, J. Jeffrey, Milpitas, CA, United States
Lewicki, John, San Jose, CA, United States
Scarborough, Robert M., Hayward, CA, United States
Porter, J. Gordon, Newark, CA, United States
PATENT ASSIGNEE(S): Scios, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5948761		19990907
APPLICATION INFO.:	US 1997-850910		19970505 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-477226, filed on 8 Feb 1990, now patented, Pat. No. US 5674710 which is a division of Ser. No. US 1989-299880, filed on 19 Jan 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-206470, filed on 14 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-200383, filed on 31 May 1988, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: LeGuyader, John L.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides of the formula R.sup.1 -Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg-Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R.sup.2

wherein R.sup.1 is selected from the group consisting of:

(H);

Gly-;

Ser-Gly-;

Lys-Ser-Gly-;

His-Lys-Ser-Gly-;

Met-His-Lys-Ser-Gly-;

Thr-Met-His-Lys-Ser-Gly-;

Lys-Thr-Met-His-Lys-Ser-Gly-;

Pro-Lys-Thr-Met-His-Lys-Ser-Gly-;

Ser-Pro-Lys-Thr-Met-His-Lys-Ser-Gly-;

or is the amino acid sequence of the dog prepro sequence upstream of position 100 shown in FIG. 8 herein or a C-terminal portion thereof;

R.sup.2 is (OH), NH.sub.2, or NR.sub.2 wherein each R is independently H or lower alkyl (1-4C) or is

Asn;

Asn-Val;

Asn-Val-Leu;

Asn-Val-Leu-Arg;

Asn-Val-Leu-Arg-Lys;

Asn-Val-Leu-Arg-Lys-Tyr;

or the amides thereof are useful in treating conditions characterized by high levels of extracellular fluid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 156 OF 179 USPATFULL on STN
ACCESSION NUMBER: 1998:159915 USPATFULL
TITLE: Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
INVENTOR(S): Sugiyama, Takashi, Hino, Japan
Kamimura, Takashi, Hino, Japan
Masuda, Kenichi, Hachioji, Japan
Okada, Masahiro, Hino, Japan
Ohtsuka, Eiko, Sapporo, Japan
Imaizumi, Atsushi, Hino, Japan
Watanabe, Kunihito, Hino, Japan
Suga, Tetsuya, Hino, Japan
Matsumoto, Yohichi, Musashino, Japan
Takeuchi, Akiko, Hino, Japan
PATENT ASSIGNEE(S): Teijin Limited, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5851983		19981222
APPLICATION INFO.:	US 1992-963538		19921020 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-843359, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1989-408483, filed on 22 Aug 1989, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1987-330219	19871228
	JP 1991-355553	19911224
	JP 1992-212398	19920717
	JP 1992-212399	19920717

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Teng, Sally
LEGAL REPRESENTATIVE: Cooley Godward LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 2648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides an elastase inhibitory polypeptide comprising a C-terminal half of a human secretory leukocyte protease inhibitor (SLPI) and having an elastase inhibitory activity wherein inhibitory activity of a trypsin-like serine protease does not exceed 1/10 of elastase inhibitory activity, and polypeptides having the above-mentioned biological activity wherein one or more than one amino acid is added, one or more than one amino acid is deleted and/or one or more than one amino acid is replaced. The present invention also provides a process for the production of the above-mentioned protein or other protein via a corresponding fused protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 157 OF 179 USPATFULL on STN
ACCESSION NUMBER: 1998:154241 USPATFULL
TITLE: Receptor specific atrial natriuretic peptides
INVENTOR(S): Lowe, David G., Brisbane, CA, United States

Cunningham, Brian C., Piedmont, CA, United States
Oare, David, Belmont, CA, United States
McDowell, Robert S., San Francisco, CA, United States
Burnier, John P., Pacifica, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5846932		19981208
APPLICATION INFO.:	US 1995-470846		19950606 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-419877, filed on 11 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1995-362552, filed on 6 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-152994, filed on 19 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Gupta, Anish
LEGAL REPRESENTATIVE: Kubinec, Jeffrey S.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 21 Drawing Figure(s); 20 Drawing Page(s)
LINE COUNT: 2208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 158 OF 179 USPATFULL on STN
ACCESSION NUMBER: 1998:143652 USPATFULL
TITLE: Method of treating heart failure using leukemia inhibitory factor antagonists optionally with endothelin antagonists
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
King, Kathleen, Pacifica, CA, United States
Luis, Elizabeth, San Francisco, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Paoni, Nicholas F., Belmont, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5837241		19981117
APPLICATION INFO.:	US 1996-693826		19960726 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-428002, filed on 24 Apr 1995, now patented, Pat. No. US 5573762
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Scheiner, Toni R.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E., Conley, Deirde L.
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 159 OF 179 USPATFULL on STN

ACCESSION NUMBER:	1998:119120 USPATFULL
TITLE:	Compounds with PTH activity
INVENTOR(S):	Oldenburg, Kevin R., Fremont, CA, United States Selick, Harold E., Belmont, CA, United States
PATENT ASSIGNEE(S):	Affymax Technologies N.V., Greenford, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814603		19980929
APPLICATION INFO.:	US 1993-142551		19931025 (8)

RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-965677, filed on 22 Oct 1992, now abandoned Ser. No. Ser. No. US 1993-77296, filed on 14 Jun 1993, now abandoned And Ser. No. US 1992-898219, filed on 12 Jun 1992, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Kemmerer, Elizabeth C.
ASSISTANT EXAMINER:	Lathrop, Brian
LEGAL REPRESENTATIVE:	Stevens, Lauren L., Kaster, Kevin R.
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	3347

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB PTH analogs comprising an amino acid sequence that is: SVSEIQLLHNX.sub.1 X.sub.2 X.sub.3 HX.sub.4 X.sub.3 X.sub.3 X.sub.3 X.sub.5 RVX.sub.5 WLR X.sub.4 X.sub.4 LX.sub.3 X.sub.3 VX.sub.1 X.sub.3 X.sub.3 X (SEQ ID NO:10) wherein X.sub.1 is a neutral or positively charged amino acid, X.sub.2 is a neutral amino acid, X.sub.3 is a neutral, positively charged, or negatively charged amino acid, X.sub.4 is a positively charged amino acid, X.sub.5 is a positively charged or negatively charged amino acid, and X is selected from the group consisting of Hol, Ho, a homoserine amide, or the sequence of amino acids comprising residues 35-84 of PTH, have enhanced activity and increased serum half-life as compared with human PTH. The PTH analogs can be produced as fusion proteins in high yields in E. coli host cells; the fusion proteins can be subsequently cleaved to produce the PTH analog.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 160 OF 179 USPATFULL on STN

ACCESSION NUMBER:	1998:22344 USPATFULL
TITLE:	Method of purifying cardiac hypertrophy factor
INVENTOR(S):	Baker, Joffre, El Granada, CA, United States Chien, Kenneth, La Jolla, CA, United States King, Kathleen, Pacifica, CA, United States Pennica, Diane, Burlingame, CA, United States Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5723585		19980303
APPLICATION INFO.:	US 1995-443130		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Borin, Michael L.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E., Conley, Deirdre L.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 161 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:112452 USPATFULL
TITLE: Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
INVENTOR(S): Wolff, Jon A., Madison, WI, United States
Duke, David J., Salem, OR, United States
Felgner, Philip L., Rancho Santa Fe, CA, United States
PATENT ASSIGNEE(S): Vical Incorporated, San Diego, CA, United States (U.S. corporation)
Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5693622		19971202
APPLICATION INFO.:	US 1995-480039		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-210628, filed on 18 Mar 1994, now abandoned which is a continuation of Ser. No. US 1991-791101, filed on 12 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-496991, filed on 21 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-467881, filed on 19 Jan 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-326305, filed on 21 Mar 1989, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Crouch, Deborah
LEGAL REPRESENTATIVE: Knobbe, Martens, Olson & Bear
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for delivering a

pharmaceutical polypeptide to the interior of a cardiac cell of a vertebrate in vivo, comprising the step of introducing a preparation comprising a pharmaceutically acceptable injectable carrier and naked polynucleotide operatively coding for the polypeptide into the interstitial space of the heart, whereby the naked polynucleotide is taken up into the interior of the cell and has a pharmacological effect on the vertebrate. In a preferred embodiment wherein the polynucleotide encodes polypeptide immunologically foreign to the vertebrate, the delivery method preferably comprises delivering an immunosuppressive agent to the vertebrate to limit immune responses directed to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 162 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:96744 USPATFULL
TITLE: Gene encoding cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679545		19971021
APPLICATION INFO.:	US 1995-443952		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994, now patented, Pat. No. US 5571893, issued on 5 Nov 1996 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615, issued on 9 Jul 1996
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Arthur, Lisa B.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E., Conley, Deirdre L.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1,8,9,10
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CT-1, isolated DNA encoding CT-1, and recombinant or synthetic methods of preparing CT-1 are disclosed. These CT-1 molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 163 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:91372 USPATFULL
TITLE: Recombinant techniques for production of human brain natriuretic peptide
INVENTOR(S): Seilhamer, J. Jeffrey, Milpitas, CA, United States
Lewicki, John, San Jose, CA, United States
Scarborough, Robert M., Hayward, CA, United States
Porter, J. Gordon, Newark, CA, United States
PATENT ASSIGNEE(S): Scios, Inc., Mountain View, CA, United States (U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674710		19971007
APPLICATION INFO.:	US 1990-477226		19900208 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-299880, filed on 19 Jan 1989, now abandoned And a continuation-in-part of Ser. No. US 1988-206470, filed on 14 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-200383, filed on 31 May 1988, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: LeGuyader, John L.
LEGAL REPRESENTATIVE: Morrison & Foerster LLP
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1,2
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1241
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 164 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:86453 USPATFULL
TITLE: Process for producing peptides in E . coli
INVENTOR(S): Yabuta, Masayuki, Tatebayashi, Japan
Suzuki, Yuji, Ashikaga, Japan
Ohsuye, Kazuhiro, Ohra-gun, Japan
Oshima, Takehiro, Ashikaga, Japan
Onai, Seiko, Isesaki, Japan
Magota, Koji, Takatsuki, Japan
Tanaka, Shoji, Ashiya, Japan
PATENT ASSIGNEE(S): Suntory Limited, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5670340		19970923
APPLICATION INFO.:	US 1994-352179		19941205 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-929597, filed on 17 Aug 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-230769	19910819
	JP 1992-223520	19920731

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Grimes, Eric
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 16 Drawing Page(s)
LINE COUNT: 1304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is a process to express a target peptide in a large amount and accumulate the target peptide in host cells in the form of inclusion bodies. The process comprises:

A) culturing host cells transformed with a plasmid able to express a gene coding for a fusion protein represented in the formula A--L--B, wherein B is a target peptide, A is a protective peptide comprising a 90-210 amino acid fragment E. coli β-galactosidase, and L is a linker peptide positioned between the C-terminus of the protective peptide and the N-terminus of the target peptide and selected so that when the fusion protein is treated by an enzyme or chemical substance, the target peptide is separated, and wherein the protective peptide and linker peptide are selected so that the isoelectric point of the fusion protein in between 4.9 and 6.9;

B) obtaining an insoluble fraction comprising inclusion bodies by homogenization of th cultured transformed cells;

C) solubilizing the fusion protein in the inclusion bodies by treatment of the insoluble fraction with a solubilizing agent; and,

D) cleaving the peptide bond between the C-terminus of the linker peptide and the N-terminus of the target peptide of the solubilized fusion protein to release the target peptide from the other peptides followed by purification of the target peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 165 OF 179 USPATFULL on STN

ACCESSION NUMBER:	97:81254 USPATFULL
TITLE:	Receptor specific atrial natriuretic peptides
INVENTOR(S):	Lowe, David, Brisbane, CA, United States Cunningham, Brian C., Piedmont, CA, United States Oare, David, Belmont, CA, United States McDowell, Robert S., San Francisco, CA, United States Burnier, John, Pacifica, CA, United States
PATENT ASSIGNEE(S):	Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5665704		19970909
APPLICATION INFO.:	US 1995-451240		19950525 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-362552, filed on 6 Jan 1995 which is a continuation-in-part of Ser. No. US 1993-152994, filed on 12 Nov 1993
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Tsang, Cecilia
ASSISTANT EXAMINER:	Gupta, Anish
LEGAL REPRESENTATIVE:	Kubinec, Jeffrey S.
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	1933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 166 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:76104 USPATFULL
TITLE: Treatment of congestive heart failure
INVENTOR(S): Clark, Ross G., Pacifica, CA, United States
Jin, Hongkui, San Bruno, CA, United States
Paoni, Nicholas F., Belmont, CA, United States
Yang, Renhui, San Bruno, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5661122		19970826
APPLICATION INFO.:	US 1994-284859		19940802 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-227923, filed on 15 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jordan, Kimberly
LEGAL REPRESENTATIVE: Hasak, Janet E., Dreger, Walter H.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 1425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods of enhancing myocardial contractility and cardiac performance in a mammal with congestive heart failure are disclosed. In a first method a mammal with congestive heart failure is treated by administering to the mammal an effective amount of a combination of growth hormone (GH) and insulin-like growth factor (IGF-I). A second method comprises administering to the mammal an effective amount of a combination of GH and IGF-I in the presence of an ACE inhibitor. This method results in enhancement of myocardial contractility and cardiac performance above the level achieved with ACE inhibition alone. Preferably the mammal is a human.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 167 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:38416 USPATFULL
TITLE: Hybridomas producing antibodies to cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., United States (U.S. corporation)
The Regents of the University of California, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5627073		19970506
APPLICATION INFO.:	US 1995-443129		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nucker, Christine M.

ASSISTANT EXAMINER: Reeves, Julie E.
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4258
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF (also referred to cardiac hypertrophy factor or cardiotrophin-1), isolated DNA encoding CHF, hybridomas and cell lines producing antibodies to CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 168 OF 179 USPATFULL on STN
ACCESSION NUMBER: 97:36067 USPATFULL
TITLE: Antibodies to cardiac hypertrophy factor and uses thereof
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624806		19970429
APPLICATION INFO.:	US 1995-442745		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Knode, Marian C.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4254
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding cardiac hypertrophy factor (CHF), and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 169 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:103736 USPATFULL
TITLE: Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac

hypertrophy
INVENTOR(S): Ferrara, Napoleone, San Francisco, CA, United States
King, Kathleen, Pacifica, CA, United States
Luis, Elizabeth, San Francisco, CA, United States
Mather, Jennie P., Millbrae, CA, United States
Paoni, Nicholas F., Belmont, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5573762		19961112
APPLICATION INFO.:	US 1995-428002		19950424 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hutzell, Paula K.
ASSISTANT EXAMINER: Johnson, Nancy A.
LEGAL REPRESENTATIVE: Torchia, Ph.D, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 170 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:101657 USPATFULL
TITLE: Cardiac hypertrophy factor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571893		19961105
APPLICATION INFO.:	US 1994-286304		19940805 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-233609, filed on 25 Apr 1994, now patented, Pat. No. US 5534615
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Hayes, Robert C.
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4056
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed, These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic

disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 171 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:101443 USPATFULL
TITLE: Detection and amplification of candiotrophin-1(cardiac hypertrophy factor)
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennica, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
Regents of the Univ. of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571675		19961105
APPLICATION INFO.:	US 1995-444083		19950517 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-286304, filed on 5 Aug 1994 which is a continuation-in-part of Ser. No. US 1994-233609, filed on 25 Apr 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Zitomer, Stephanie W.
ASSISTANT EXAMINER: Fredman, Jeffrey
LEGAL REPRESENTATIVE: Torchia, Timothy E., Hasak, Janet E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 4298
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 172 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:60798 USPATFULL
TITLE: Cardiac hypertrophy factor and uses therefor
INVENTOR(S): Baker, Joffre, El Granada, CA, United States
Chien, Kenneth, La Jolla, CA, United States
King, Kathleen, Pacifica, CA, United States
Pennice, Diane, Burlingame, CA, United States
Wood, William, San Mateo, CA, United States
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5534615		19960709
APPLICATION INFO.:	US 1994-233609		19940425 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wax, Robert A.

ASSISTANT EXAMINER: Kim, Hyosuk
LEGAL REPRESENTATIVE: Hasak, Janet E., Torchia, Timothy E.
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 3897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 173 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:46150 USPATFULL
TITLE: Nucleic acids encoding hybrid receptor molecules
INVENTOR(S): Pacifici, Robert E., Thousand Oaks, CA, United States
Thomason, Arlen R., Thousand Oaks, CA, United States
PATENT ASSIGNEE(S): Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5521295		19960528
APPLICATION INFO.:	US 1994-336708		19941108 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-73196, filed on 7 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jones, W. Gary
ASSISTANT EXAMINER: Schreiber, David
LEGAL REPRESENTATIVE: Oleski, Nancy]>
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1017
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Provided are hybrid receptor molecules wherein one domain of the receptor is derived from the cytokine superfamily of receptors and other domain is derived from a heterologous family of receptors. Also provided are methods for identifying ligands that bind to the hybrid receptor molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 174 OF 179 USPATFULL on STN
ACCESSION NUMBER: 96:36456 USPATFULL
TITLE: Atrial natriuretic peptide receptor protein
INVENTOR(S): Schenk, Dale B., Campbell, CA, United States
PATENT ASSIGNEE(S): Scios Nova, Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5512455		19960430
APPLICATION INFO.:	US 1987-48296		19870511 (7)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1986-861529, filed on 9 May 1986, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted

PRIMARY EXAMINER: Low, Christopher S. F.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 14 Drawing Page(s)
LINE COUNT: 1309
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Purified native Atrial Naturetic Peptide (ANP) receptor protein is provided, as well as synthetic ANP receptor and methods of making and using ANP receptor protein and antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 175 OF 179 USPATFULL on STN
ACCESSION NUMBER: 94:86317 USPATFULL
TITLE: Compositions and methods for the synthesis of natriuretic protein receptor B and methods of use
INVENTOR(S): Chang, Ming-Shi, Newbury Park, Canada
Goeddel, David V., Hillsborough, Canada
Lowe, David G., Brisbane, Canada
PATENT ASSIGNEE(S): Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5352587		19941004	
	WO 9100292		19910110	
APPLICATION INFO.:	US 1991-778157		19911219	(7)
	WO 1990-US3586		19900622	
			19911219	PCT 371 date
			19911219	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1989-370673, filed on 23 Jun 1989, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Teng, Sally P.
LEGAL REPRESENTATIVE: Lee, Wendy M., Fitts, Renee A.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 1811
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described are the amino acid sequence of natriuretic peptide receptor B (NPRB) and DNA encoding NPRB. Also disclosed are expression vectors and cells transformed to express the NPRB, DNA encoding NPRB and diagnostic and therapeutic uses for the NPRB and the DNA encoding NPRB.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 176 OF 179 USPATFULL on STN
ACCESSION NUMBER: 94:53530 USPATFULL
TITLE: Expression of recombinant polypeptides with improved purification
INVENTOR(S): Tarnowski, S. Joseph, Sunnyvale, CA, United States
Hilliker, Sandra, Riverside, CA, United States
Willett, W. Scott, San Francisco, CA, United States
PATENT ASSIGNEE(S): Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 5322930 19940621
APPLICATION INFO.: US 1992-974932 19921112 (7)
RELATED APPLN. INFO.: Division of Ser. No. US 1990-564259, filed on 19 Aug 1990, now patented, Pat. No. US 5202239
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Hill, Jr., Robert J.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 177 OF 179 USPATFULL on STN
ACCESSION NUMBER: 93:29119 USPATFULL
TITLE: Expression of recombinant polypeptides with improved purification
INVENTOR(S): Tarnowski, S. Joseph, Sunnyvale, CA, United States
Hilliker, Sandra, Riverside, CA, United States
Willett, W. Scott, San Francisco, CA, United States
PATENT ASSIGNEE(S): Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5202239		19930413	
APPLICATION INFO.:	US 1990-564259		19900807	(7)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Draper, Garnette D.
ASSISTANT EXAMINER: Ulm, John D.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 10 Drawing Page(s)
LINE COUNT: 838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved method for expressing peptides as fusion proteins, uses a carrier for a heterologous peptide to provide a fusion protein having a high pI. The high isoelectric point facilitates separation of the fusion protein from all other host cell proteins, and separation of the carrier from the peptide after cleavage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 178 OF 179 USPATFULL on STN
ACCESSION NUMBER: 92:40648 USPATFULL
TITLE: Recombinant techniques for production of novel natriuretic and vasodilator peptides
INVENTOR(S): Seilhamer, Jeffrey J., Milpitas, CA, United States
Lewicki, John A., Los Gatos, CA, United States
Scarborough, Robert M., Belmont, CA, United States
Porter, J. Gordon, Newark, CA, United States
PATENT ASSIGNEE(S): California Biotechnology Inc., Mountain View, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5114923		19920519	
APPLICATION INFO.:	US 1990-460855		19900202	(7)
	WO 1989-US2373		19890531	
			19900202	PCT 371 date
			19900202	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1988-299880, filed on 19 Jan 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-206470, filed on 14 Jun 1988, now abandoned which is a continuation-in-part of Ser. No. US 1988-200383, filed on 31 May 1988, now abandoned

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Cashion, Jr., Merrell C.
ASSISTANT EXAMINER: Perkins, Susan M.
LEGAL REPRESENTATIVE: Morrison & Foerster
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 1182
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of? ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof;

R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) is

R.sup.1 -Cys-Phe-Gly-Arg-Arg-Leu-Asp-Arg- Ile-Gly-Ser-Leu-Ser-Gly-Leu-Gly-Cys-R.sup.2

and R.sup.1 is Asp-Ser-Gly-, R.sup.2 cannot be Asn-Val-Leu-Arg-Arg-Tyr.

The peptides of the invention can be formulated into pharmaceutical compositions and used to treat conditions associated with high extracellular fluid levels, especially congestive heart failure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 179 OF 179 PROMT COPYRIGHT 2006 Gale Group on STN

ACCESSION NUMBER:	89:285008 PROMT
TITLE:	Product information section. (Clinical Laboratory Reference 1989) (buyers guide)
SOURCE:	Medical Laboratory Observer, (Annual 1989) Vol. 21, No. 13, pp. 16(90).
	ISSN: ISSN: 0580-7247.
PUBLISHER:	Nelson Publishing
DOCUMENT TYPE:	Newsletter
LANGUAGE:	English
WORD COUNT:	61023

FULL TEXT IS AVAILABLE IN THE ALL FORMAT

AB PRODUCT INFORMATION SECTION
THIS IS THE FULL TEXT: COPYRIGHT 1989 Nelson Publishing

Subscription: $65.00 per year. Published monthly. 2500 N. Tamiami Trail, Nokomis, FL 34275-3482.

=> d his

(FILE 'HOME' ENTERED AT 13:29:35 ON 19 DEC 2006)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, FOMAD, ...' ENTERED AT 13:29:53 ON 19 DEC 2006

L1 129634 S METHOD AND PRODUCE AND PEPTIDES
L2 70156 S ATRIAL NATRIURETIC PEPTIDE
L3 1046 S L1 AND L2
L4 425 S L3 AND E.COLI
L5 389 S L4 AND RECOMBINANT
L6 348 DUP REM L5 (41 DUPLICATES REMOVED)
L7 179 S L6 AND ANP
L8 179 DUP REM L7 (0 DUPLICATES REMOVED)
L9 0 S L8 AND O-ACETYSERINE
L10 0 S L8 AND O-ACETYLSERINE

Search Forms
Search Results
Help
User Searches
Preferences
Logout

Refine Search

Search Results -

Term	Documents
METHOD	9532521
METHODS	2440543
PRODUCE	3541500
PRODUCES	1388572
PEPTIDE	206967
PEPTIDES	150780
(11 AND ((PRODUCE ADJ PEPTIDE) SAME METHOD)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	1
(L11 AND METHOD SAME PRODUCE PEPTIDE).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	1

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L12

Refine Search

Recall Text | Clear | Interrupt

Search History

DATE: Tuesday, December 19, 2006 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES; OP=ADJ			
L12	L11 and method same produce peptide	1	L12
L11	L10 and recombinant	33	L11
L10	L9 and E.coli	41	L10

L9	atrial natriuretic peptide	1732	L9
L8	L7 and methods and recombinantion	1	L8
L7	ANP	6527	L7
L6	L4 and histidine	294	L6
L5	L4 and O-acetylserine	1	L5
L4	L3 and methionine	334	L4
L3	L2 and E.coli	454	L3
L2	L1 and recombination	7882	L2
L1	protein production	15619	L1

END OF SEARCH HISTORY